The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...

Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat ...

The Danish drugmaker asked the agency to put semaglutide, the active ingredient in Wegovy and Ozempic, on a list of drugs ...

Pharmaceutical giant Novo Nordisk plans to use Denmark's first sovereign artificial intelligence supercomputer—powered by ...

Ozempic maker Novo Nordisk (NVO) is asking the U.S. Food and Drug Administration (FDA) to prohibit compounding pharmacies ...

Novo Nordisk NVO has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of ...

Novo Nordisk just hit a technical red flag with a Death Cross, but its strong fundamentals suggest a potential rebound.

Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.

On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.

Under US law, compounding pharmacies can make and sell patent-protected drugs that are on the FDA's shortages list in limited ...

Novo Nordisk has requested that the FDA prohibit compounding pharmacies from producing unapproved versions of its popular weight loss and diabetes drugs, Wegovy and Ozempic, CNBC reported Oct. 23. The ...